REGENXBIO Inc. (RGNX) financial statements and ratios from SEC XBRL: revenue $170.44M (TTM), net margin -113.8%, revenue growth -92.8% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $170.44M |
| Net Margin | -113.8% |
| Revenue Growth (YoY) | -92.8% |
| EPS Growth (YoY) | -1533.3% |
| FCF Growth (YoY) | -337.5% |
| Price / Book | 26.25 |
| Price / Sales | 6.30 |
| FCF Yield | -42.7% |
| Altman Z-Score | -2.90 (distress) |
| Sector P/E (Healthcare) | 21.7 |
RGNX overview · RGNX earnings · RGNX KPIs · RGNX investor relations · RGNX ownership · RGNX peers · RGNX filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.